The global rapid antigen testing market is expected to grow steadily over the next decade, driven by increasing demand for quick and cost-effective diagnostic solutions for infectious diseases. Rapid antigen tests provide near-instant results by detecting specific proteins on the surface of pathogens, making them invaluable tools for early diagnosis and effective disease management.
These tests have gained prominence not only for respiratory illnesses such as COVID-19 and influenza but also for other infectious diseases where timely identification is crucial. In 2025, the global rapid antigen testing market is estimated to be valued at approximately USD 27,786.6 Million. By 2035, it is projected to grow to around USD 55,173.4 Million, reflecting a compound annual growth rate (CAGR) of 7.1%.
Key Market Metrics
| Metric | Value |
|---|---|
| Market Size in 2025 | USD 27,786.6 Million |
| Projected Market Size in 2035 | USD 55,173.4 Million |
| CAGR (2025 to 2035) | 7.1% |
As healthcare systems emphasize quicker diagnostics, better accessibility, and large-scale testing capabilities, the adoption of rapid antigen tests is expanding across hospitals, clinics, pharmacies, and even at-home use. Advances in test accuracy, integration with digital health platforms, and streamlined regulatory approvals are further supporting the market’s consistent growth through 2035.
Explore FMI!
Book a free demo
Driven by a well-established healthcare infrastructure, high demand for point-of-care diagnostics, and strong public health initiatives, North America will continue to be a key market for rapid antigen testing. Meanwhile, the USA and Canada are showing increasing use of rapid antigen tests in both clinical and home settings.
Europe is the other major market as the governments across countries invest significantly in health care preparedness, at-home testing kits are widely used and distribution channels are well-established. In Germany, the United Kingdom, and France, rapid antigen testing for infectious diseases and seasonal illnesses is widely deployed.
The Asia-Pacific is the leading rapidly-growing market for rapid antigen testing worldwide, which is attributed to the large populations of several countries in the region as well as expanded access to healthcare facilities and increased awareness about early diagnosis.
Countries like China, India and Japan are showing rising demand for inexpensive and simple to use diagnostic solutions, supported by continuing public health campaigns and enhancing health care infrastructure. The increasing concentration on pandemic preparedness and infection control in the region is likely to be a key growth driver for the global rapid antigen testing market.
Challenges
Sensitivity Variability, Regulatory Compliance, and Waste Management
Challenges for the rapid antigen testing market are ongoing, especially regarding the sensitivity and specificity of the antigen-based tests in comparison to PCR-based molecular diagnostics. While rapid antigen tests provide quick results, they are less sensitive in low viral loads or asymptomatic cases, and can result in false negatives which make them unsuitable for high accuracy screening settings.
Additionally, frequent amendments to regulatory protocols by agencies such as FDA, WHO, and EMA are resulting in delays of attractive product approvals or necessitating repeated product revalidation, mainly related with point-of-care and at-home test kits.
From an environmental perspective, there should be a concern since the single-use nature of the test kits, such as plastic cassettes, swabs and reagents, generates a large amount of biomedical waste that is of limited recyclability.
Opportunities
Decentralized Testing, Multiplex Diagnostics, and Pandemic Preparedness
Despite these challengesthe rapid antigen testing market is yielding significant allocation in response to the growing need for fast, point-of-care diagnostics in decentralized and resource-constrained environments. These tests are critical for outbreak control, border screening and mass testing programs particularly during outbreaks of respiratory, gastrointestinal and tropical infections.
As health care trends towards home-based care, integration of telemedicine systems, and preparation for emerging public health threats, rapid antigen tests are already being expanded into areas beyond COVID-19, such as testing for influenza, RSV, dengue, malaria and streptococcus.
Recent technological advances, including the coupling of digital lateral flow readers, smartphone-based detection, and multiplex antigen platforms are enabling rapid tests to become connected diagnostics, allowing for real-time surveillance and data-driven decision-making.
| Market Shift | 2020 to 2024 Trends |
|---|---|
| Regulatory Landscape | Emergency use authorizations (EUAs), evolving performance benchmarks, and region-specific compliance. |
| Consumer Trends | High uptake of COVID-19 self-tests and travel-related screening kits. |
| Industry Adoption | Deployed in hospitals, pharmacies, airports, and diagnostic labs. |
| Supply Chain and Sourcing | Reliant on monoclonal antibodies, nitrocellulose membranes, and plastic components. |
| Market Competition | Led by Abbott, SD Biosensor, QuidelOrtho, Roche Diagnostics, and Becton Dickinson. |
| Market Growth Drivers | Boosted by COVID-19 mass testing and pandemic response investments. |
| Sustainability and Environmental Impact | Minimal focus beyond safe disposal protocols. |
| Integration of Smart Technologies | Use of QR-coded results, connected mobile apps, and cloud-based data logging. |
| Advancements in Test Design | Use of lateral flow immunoassays (LFIAs) and colloidal gold-based detection. |
| Market Shift | 2025 to 2035 Projections |
|---|---|
| Regulatory Landscape | Standardization of global antigen test quality criteria, data sharing protocols, and AI-aided result validation. |
| Consumer Trends | Rising adoption of at-home infectious disease test kits and multi-pathogen screening. |
| Industry Adoption | Expansion into workplace testing, elder care, schools, and low-resource clinics. |
| Supply Chain and Sourcing | Shift to biodegradable test materials, 3D-printed components, and regionalized test kit production. |
| Market Competition | Entry of multiplex testing startups, digital diagnostics innovators, and localized test manufacturing hubs. |
| Market Growth Drivers | Driven by early disease detection, global health security mandates, and diagnostic decentralization. |
| Sustainability and Environmental Impact | Introduction of eco-packaging, reusable test platforms, and biodegradable swab and buffer materials. |
| Integration of Smart Technologies | Advancement into AI-assisted diagnostics, Bluetooth-linked readers, and population-level test tracking. |
| Advancements in Test Design | Innovation into fluorescent nanoparticle tagging, quantum-dot detection, and microfluidic test platforms. |
The USA's rapid antigen testing market is experiencing steady growth, against a backdrop of sustained demand for fast, point-of-care diagnostics for use in respiratory and infectious disease surveillance. The healthcare system’s efforts around preparedness, workplace screening and homebased testing are supportive of sustained market activity. Furthermore, their availability at CLIA-waived testing sites and OTC is further driving market penetration.
| Country | CAGR (2025 to 2035) |
|---|---|
| USA | 7.2% |
In the United Kingdom, routine use of rapid antigen tests across schools, workplaces and community health centers support market growth. Adoption is also driven by government initiatives aimed at early detection and the decentralized testing infrastructure, as well as the growth of pharmacy-based diagnostic services.
| Country | CAGR (2025 to 2035) |
|---|---|
| UK | 7.0% |
Rapid antigen testing business, driven by factors like pandemic preparedness, surveillance programs, and faster clinical triage tools across Europe, leading to the growth of this market. The need for cost-effective, fast, and scalable diagnostic kits is still in demand, specifically for respiratory pathogens, STDs, and gastrointestinal infections. Regulatory backing for self-testing is also helping to drive adoption.
| Region | CAGR (2025 to 2035) |
|---|---|
| European Union (EU) | 7.1% |
Japan’s market is growing at a steady pace, driven by healthcare needs in an aging population, spreading out for mass screening against diseases among long-term care facilities, and increasing demand for point-of-care diagnostics in outpatient services. This trend is being accelerated by public and private health providers toward reader-free, portable formats for rapid tests.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 7.0% |
The growth of this market is attributed to technological developments in lateral flow assay platforms, government support of rapid testing in times of outbreaks, and use in corporate, school, and military environments in the South Korean region. The domestic manufacturing and export of multiplex rapid antigen kits is also strengthening the country’s position in global market.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 7.2% |
Rapid antigen testing market can be attributed to growing healthcare systems focus on early diagnosis, real-time infection tracking, and cost-effective point-of-care testing. These tests can be performed on the spot, require little training to use, and do not necessitate elaborate laboratory infrastructure, so they are vital for screening and surveillance in clinical, home-based, and decentralized care settings.
In the wake of infectious and non-communicable diseases, demand for antigen-based assays is booming whether you are in a high- or low-resource setting. Market Segmentation include: By Technique (Immunosorbent Assay, Enzyme-linked Immunosorbent, Precipitation Reaction, Radioimmunoassay, Agglutination Reaction, Complement Fixation) By Application (Sexually Transmitted Diseases, Autoimmune Diseases, Tropical Diseases, Liver Diseases).
| Technique | Market Share (2025) |
|---|---|
| Immunosorbent Assay | 37.4% |
Considerably early immunosorbent assays are estimated to dominate the global market for rapid antigen tests with a market share of 37.4% by 2025. These assays are characterized by high specificity, low sample preparation, and compatibility with a wide variety of analyses. They have been widely used in the detection of antigens in respiratory, gastrointestinal, and sexually transmitted infections.
The scalability of the immunosorbent techniques based formats has made them the basis of lab-based as well as point-of-care rapid test kits, addressing the need for COVID-19 tests. This segment is also expected to maintain leading positions across clinical diagnostics and public health screening programs with continued innovation in lateral flow and microplate formats.
| Application | Market Share (2025) |
|---|---|
| Sexually Transmitted Diseases | 33.1% |
The sexually transmitted diseases (STDs) segment will dominate the application segment, with a market share of 33.1% over the global market, in 2025. One of the most widely used rapid antigen tests are used to diagnose STDs such as HIV, syphilis, chlamydia and gonorrhea in places with limited resources like community health centers and STI clinics where timely diagnosis is very important.
However, point-of-care tests aid treatment decisions at the time of presentation, limit transmission potential, and improve disease surveillance and public health response. Global initiatives to address the increasing prevalence to STDs as well as provide diagnostics options to the underserved population in most regions would continue driving the application segment of rapid antigen testing solution on positive growth trajectory enabling innovations.
Although they are identified as a smaller portion of infectious disease diagnostics, the rapid antigen testing market is also attractive and also supports accelerative surveillance for COVID-19 and other respiratory pathogens, including influenza and RSV.
These tests are valued for being fast, cheap, and point-of-care. Companies are making multiplex antigen detection kits in addition to digital readout integration for test results and self-testing kits, compatible with global health preparedness strategies.
Market Share Analysis by Company
| Company Name | Estimated Market Share (%) |
|---|---|
| Abbott Laboratories | 22-26% |
| Roche Diagnostics | 18-22% |
| Siemens Healthineers AG | 12-16% |
| QuidelOrtho Corporation | 8-12% |
| SD Biosensor, Inc. (with Roche) | 6-9% |
| Other Companies (combined) | 20-25% |
| Company Name | Key Offerings/Activities |
|---|---|
| Abbott Laboratories | In 2024, expanded BinaxNOW™ platform with combo antigen tests for COVID-19 and flu. In 2025, integrated Bluetooth-enabled test readers for home monitoring and digital health syncing. |
| Roche Diagnostics | In 2024, upgraded SARS-CoV-2 Rapid Antigen Test 2.0 with improved specificity. In 2025, introduced multi-pathogen antigen panels for respiratory infections through its partnership with SD Biosensor. |
| Siemens Healthineers | In 2024, launched CLINITEST® rapid antigen combo kits with professional and OTC versions. In 2025, focused on school-based surveillance and low-resource clinical settings globally. |
| QuidelOrtho Corporation | In 2024, introduced next-gen QuickVue® At-Home COVID-19 and Flu Test. In 2025, scaled production of CLIA-waived multiplex kits for primary care and urgent care clinics. |
| SD Biosensor, Inc. | In 2024, rolled out enhanced STANDARD Q kits with quantitative readout capabilities. In 2025, expanded presence in Southeast Asia and LATAM through WHO-prequalified product lines. |
Key Company Insights
Abbott Laboratories (22-26%)
Abbott dominates the global market through its BinaxNOW™ and Panbio™ platforms, offering reliable, fast, and accessible rapid antigen tests. The company continues to push innovation in home diagnostics and digital health integration.
Roche Diagnostics (18-22%)
Roche, in partnership with SD Biosensor, provides high-performance antigen test kits with global distribution, focusing on dual testing formats and public health readiness in both developed and emerging markets.
Siemens Healthineers (12-16%)
Siemens offers flexible rapid testing solutions, especially for community health programs, and integrates clinical-grade accuracy with mobile reader technologies.
QuidelOrtho (8-12%)
Quidel excels in CLIA-waived antigen test kits that balance accuracy, portability, and simplicity, with strong penetration in USA retail and point-of-care markets.
SD Biosensor (6-9%)
SD Biosensor is a global supplier known for cost-effective, scalable antigen test solutions, often under co-branded partnerships with Roche. It plays a pivotal role in pandemic preparedness initiatives in Asia and Africa.
Other Key Players (20-25% Combined)
The overall market size for the rapid antigen testing market was USD 27,786.6 Million in 2025.
The rapid antigen testing market is expected to reach USD 55,173.4 Million in 2035.
Growth is driven by the increasing demand for fast and cost-effective diagnostic solutions, rising prevalence of infectious diseases, expansion of point-of-care testing facilities, and growing adoption of self-testing kits for early disease detection.
The top 5 countries driving the development of the rapid antigen testing market are the USA, China, India, Germany, and Brazil.
Immunosorbent Assay and Sexually Transmitted Diseases (STDs) Applications are expected to command a significant share over the assessment period.
CGRP Inhibitors Market Trends - Growth, Demand & Forecast 2025 to 2035
Indolent Systemic Mastocytosis treatment Market Insights: Size, Trends & Forecast 2025 to 2035
Intraoperative Fluorescence Imaging Market Report - Demand, Trends & Industry Forecast 2025 to 2035
Cardiovascular Diagnostics Market Report- Trends & Innovations 2025 to 2035
Venous Ulcer Treatment Market Overview - Growth, Trends & Forecast 2025 to 2035
Leukocyte Adhesion Deficiency Management Market - Innovations & Treatment Trends 2025 to 2035
Rapid Antigen Testing Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
